BioSpace23h
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
BioSpace2dOpinion
Opinion: Drugs Are Becoming ‘Smarter.’ Here’s How
Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
FierceBiotech29d
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
Financial Post29d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
Pharmaceutical Technology29d
Boehringer partners WHO Foundation to advance healthcare access
Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...
Business Wire1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...